1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
5
Active Trials
200 recruiting
1
Rare Diseases
across 9 areas
0
News (30d)
Quiet
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. is a company with 1 orphan drug designation across 1 rare disease. Active clinical trials in 5 indications. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| breast cancer | - | Des.TrialAppr. |
| cancer | - | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| mature T-cell and NK-cell non-Hodgkin lymphoma | Mitoxantrone hydrochloride liposome | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
49
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
49
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio